Outside of a clinical trial, how do you approach upfront therapy for a PDGFRA D842V-mutant GIST?
Would your recommendations change in the neoadjuvant versus adjuvant or metastatic setting?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Washington University School of Medicine
Answered on
These are usually indolent surgical tumors (until they are not) that belong in the care of a sarcoma center and not in the community. There are two trials of agents that are being tested for D842V mutations at this time (NCT02508532 and NCT02847429).
Join for free or sign in to see the full answer